Thiery-Vuillemin, A., Saad, F., Armstrong, A. J., Oya, M., Vianna, K., Ozguroglu, M., … Clarke, N. (2023). Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Thiery-Vuillemin, Antoine, Fred Saad, Andrew J. Armstrong, Mototsugu Oya, Karina Vianna, Mustafa Ozguroglu, Craig Gedye, et al. “Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Thiery-Vuillemin A, Saad F, Armstrong AJ, Oya M, Vianna K, Ozguroglu M, et al. Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Thiery-Vuillemin, Antoine, et al. “Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Thiery-Vuillemin A, Saad F, Armstrong AJ, Oya M, Vianna K, Ozguroglu M, Gedye C, Buchschacher GL, Lee JY, Emmenegger U, Navratil J, Virizuela J, Salazar A, Maillet D, Uemura H, Hosius C, De Champlain A, Barker L, Degboe AN, Clarke N. Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial. JOURNAL OF CLINICAL ONCOLOGY. 2023.